Company intelligence / Profile preview
Nuravax
Irvine, California, United Statesnuravax.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Nuravax is developing immunotherapies for neurodegenerative disorders using their proprietary MultiTEP platform. Their vaccines aim to induce antibodies against pathological proteins associated with Alzheimer's and Parkinson's diseases. All programs are currently in preclinical stage.
- Therapeutic areas
- Neurology
- Modalities
- Therapeutic vaccinesDNA vaccinesmRNA vaccines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Institute for Molecular Medicine (IMM)
Beyond the preview
Go deeper on Nuravax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuravax.